- SKYRIZI® is an interleukin-23 (IL-23) inhibitor used for the
treatment of moderate to severe plaque
psoriasis.1
- In clinical studies, SKYRIZI® significantly improved levels
of skin clearance after just 16 weeks and maintained clearance at
one year (52 weeks).1
- Prince Edward Island lists
SKYRIZI® on its Pharmacare Formulary
effective February 22,
2021.
- SKYRIZI® is now listed for public payer coverage across all
Canadian jurisdictions.
MONTRÉAL, Feb. 24, 2021 /CNW/
- AbbVie (NYSE: ABBV), a global, research and
development-based biopharmaceutical company, announced today that
SKYRIZI® (risankizumab) is now listed as a special authorization
drug on the formulary of Prince Edward
Island for the treatment of moderate to severe plaque
psoriasis. With the addition of the PEI formulary listing,
SKYRIZI® is now listed for public payer coverage in all Canadian
jurisdictions.
SKYRIZI® is part of a collaboration between Boehringer Ingelheim
and AbbVie, with AbbVie leading development and commercialization
globally.
"New psoriasis treatments, which improve the quality of patients
lives, are always welcome. In clinical trials, SKYRIZI®
demonstrated high levels of skin clearance and persistence of
effect. It is great news to know that people living in PEI
with moderate-to-severe psoriasis, can now access this drug under
the provincial formulary," shares Dr. Catherine Rodriguez, MD, FRCPC,
Dermatologist.
Psoriasis is a chronic condition affecting 125 million people
worldwide, including 1 million Canadians, and many patients despite
treatment still do not reach their goals or lose treatment response
over time.2-4 The most common form is plaque
psoriasis, which affects approximately 90% of patients.
5
"Psoriasis is a burdensome disease. The first biologic was
approved in 2004 in Canada. Since
then, research on different triggers of the disease has led to
other classes of medication. The newest are the IL-23
inhibitors that have greatly improved outcomes", states Dr. Ron
Vender, MD, FRCPC, Dermatologist. "Working with SKYRIZI for
four years, as I was involved in the clinical trials, I have
witnessed that many of my SKYRIZI patients have experienced
complete skin clearance - and with only four maintenance doses per
year, the effects last. Ontario was the first province to publicly
reimburse SKYRIZI - so good to hear that it is now accessible to
all Canadians coast-to-coast."
As psoriasis causes a great physical, emotional, and social
burden, quality of life in general is often significantly
impaired. Early diagnosis and appropriate therapy give the
best chance to prevent psoriasis patients from unnecessary
suffering, and irreversible disability. Optimum therapy also
reduces societal costs of the disease. 6
Information regarding specific reimbursement criteria may be
found by consulting the link below:
- Prince Edward Island Pharmacare Bulletin
About SKYRIZI®
SKYRIZI® is a novel, humanized immunoglobulin monoclonal antibody
designed to selectively inhibit IL-23, a naturally occurring
cytokine involved in inflammatory and immune
responses.1 On April 17,
2019, SKYRIZI™ received a NOC from Health Canada for the
treatment of moderate to severe plaque psoriasis in patients who
are candidates for systemic therapy or phototherapy, based on
results from clinical studies showing significant improvement in
levels of skin clearance after just 16 weeks and at 52 weeks with
every 3-month dosing in more than 2000 adult patients.1
Four pivotal Phase 3 studies, ultIMMa-1, ultIMMa-2,
IMMvent and IMMhance evaluated more than 2,000 patients with
moderate to severe plaque psoriasis.4 Canadians living
with moderate to severe plaque psoriasis were well represented in
all four of the pivotal clinical trials leading to Health Canada's
approval, showing the Canadian leadership in this clinical
development program.
About AbbVie in Dermatology
For more than a decade,
AbbVie has worked to uncover new solutions and improve care for
people with serious skin diseases. With a broad clinical trial
program, we continue to actively research and adapt to the evolving
needs of the dermatology community and advance our pipeline to help
people achieve their treatment goals and live beyond their skin
disease.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines that solve serious health issues today
and address the medical challenges of tomorrow. We strive to have a
remarkable impact on people's lives across several key therapeutic
areas: immunology, oncology, neuroscience, eye care, virology,
women's health and gastroenterology, in addition to products and
services across its Allergan Aesthetics portfolio. For more
information about AbbVie, please visit us
at www.abbvie.ca and www.abbvie.com. Follow
@abbvieCanada and @abbvie on Twitter or view careers on
our Facebook or LinkedIn page.
References:
|
|
|
1.
|
SKYRIZI® (risankizumab) [Canadian
Product Monograph]. AbbVie Corporation, September 24,
2020.
|
2.
|
International
Federation of Psoriasis Associations. Accessed March 22, 2019.
Available
at: https://ifpa-pso.com/wp-content/uploads/2017/01/Brochure-Psoriasis-is-a-serious-disease-deserving-global-attention.pdf.
|
3.
|
Mroweitz, U., et al.
Definition of treatment goals for moderate to severe psoriasis: a
European consensus. Arch Dermatol Res. 2011 Jan; 303(1):
1–10.
|
4.
|
Levin, et al.
Biologic fatigue in psoriasis. J Dermatolog Treat. 2014
Feb;25(1):78-82. doi: 10.3109/09546634.2013.826341.
|
5.
|
Canadian Dermatology
Association – Psoriasis. Accessed on September 30, 2020.
|
6.
|
World Health
Organisation Psoriasis Information Sheet. February 6, 2016.
Available at
https://www.who.int/docs/default-source/ncds/psoriasis-info-sheet-3.pdf?sfvrsn=a5d14e81_2.
|
SOURCE AbbVie Canada